1-7 of 7
Jill Kolesar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie L. Lau, Lynette Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1604–1611.
https://doi.org/10.1158/1078-0432.CCR-20-4084
Published: 15 March 2021
View article titled, Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903)
Open the PDF for Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903) in another window
Includes: Supplementary data
Journal Articles

Abstract PO009: Increased DACH1 mutation frequency in a Kentucky hospital uterine cancer population

McKayla Riggs, Nan Lin, Chi Wang, Dava Piecoro, Rachel Miller, Oliver Hampton, Mahadev Rao, Frederick Ueland, Jill Kolesar
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3_Supplement): PO009.
https://doi.org/10.1158/1557-3265.ENDOMET20-PO009
Published: 01 February 2021
View article titled, Abstract PO009: Increased DACH1 mutation frequency in a Kentucky hospital uterine cancer population
Journal Articles

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate

Glenn Liu, Robert Jeraj, Matt Vanderhoek, Scott Perlman, Jill Kolesar, Michael Harrison, Urban Simoncic, Jens Eickhoff, Lakeesha Carmichael, Bo Chao, Rebecca Marnocha, Percy Ivy, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7634–7644.
https://doi.org/10.1158/1078-0432.CCR-11-1677
Published: 18 December 2011
View article titled, Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate
Open the PDF for Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate in another window
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

Glenn Liu, Jill Kolesar, Douglas G. McNeel, Catherine Leith, Kathy Schell, Jens Eickhoff, Fred Lee, Anne Traynor, Rebecca Marnocha, Dona Alberti, James Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-07-1490
Published: 01 May 2008
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View article titled, Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window
Journal Articles

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer

Christopher Sweeney, Glenn Liu, Constantin Yiannoutsos, Jill Kolesar, Dorothea Horvath, Mary Jane Staab, Karen Fife, Victoria Armstrong, Anthony Treston, Carolyn Sidor, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6625–6633.
https://doi.org/10.1158/1078-0432.CCR-05-0440
Published: 15 September 2005
View article titled, A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer
Open the PDF for A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

Lynn Van Ummersen, Kim Binger, Jennifer Volkman, Rebecca Marnocha, Kendra Tutsch, Jill Kolesar, Rhoda Arzoomanian, Dona Alberti, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7450–7456.
https://doi.org/10.1158/1078-0432.CCR-03-0406
Published: 29 November 2004
View article titled, A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer in another window